Orum Therapeutics, Inc. (KOSDAQ:475830)
South Korea
· Delayed Price · Currency is KRW
82,200
+500 (0.61%)
At close: Dec 5, 2025
Orum Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Revenue | 25.48 | 20,906 | 135,418 | 75.92 |
| Revenue Growth (YoY) | -99.98% | -84.56% | 178270.49% | - |
| Cost of Revenue | 0.26 | 1.99 | - | 0.83 |
| Gross Profit | 25.22 | 20,904 | 135,418 | 75.09 |
| Selling, General & Admin | 11,050 | 9,158 | 19,054 | 9,083 |
| Research & Development | 26,854 | 17,043 | 18,706 | 33,168 |
| Other Operating Expenses | 117.97 | 170.3 | 280.11 | 182.18 |
| Operating Expenses | 41,435 | 29,239 | 39,811 | 43,723 |
| Operating Income | -41,410 | -8,335 | 95,607 | -43,648 |
| Interest Expense | -1,891 | -1,794 | -824.35 | -75.37 |
| Interest & Investment Income | 1,662 | 3,179 | 560.83 | 671 |
| Currency Exchange Gain (Loss) | -2,869 | -4,609 | -5,642 | -799.86 |
| Other Non Operating Income (Expenses) | 5,657 | 5,445 | -21,199 | -19,197 |
| EBT Excluding Unusual Items | -38,851 | -6,114 | 68,502 | -63,050 |
| Gain (Loss) on Sale of Investments | 2,479 | 799.27 | -809.55 | -52.63 |
| Gain (Loss) on Sale of Assets | 66.12 | - | 205.25 | 8.91 |
| Pretax Income | -36,306 | -5,315 | 67,898 | -63,093 |
| Income Tax Expense | 575.43 | 424.98 | -319.02 | 225.34 |
| Net Income | -36,882 | -5,740 | 68,217 | -63,319 |
| Net Income to Common | -36,882 | -5,740 | 68,217 | -63,319 |
| Shares Outstanding (Basic) | 20 | 14 | 5 | 5 |
| Shares Outstanding (Diluted) | 20 | 18 | 15 | 5 |
| Shares Change (YoY) | -79.35% | 20.20% | 227.30% | - |
| EPS (Basic) | -1833.89 | -423.62 | 14829.83 | -13764.93 |
| EPS (Diluted) | -2048.72 | -555.93 | 5646.14 | -13764.93 |
| Free Cash Flow | -35,306 | -12,545 | 93,117 | -41,888 |
| Free Cash Flow Per Share | -1755.52 | -693.22 | 6184.75 | -9106.02 |
| Gross Margin | 98.99% | 99.99% | 100.00% | 98.91% |
| Operating Margin | -162507.51% | -39.87% | 70.60% | -57492.65% |
| Profit Margin | -144736.86% | -27.46% | 50.38% | -83402.60% |
| Free Cash Flow Margin | -138552.19% | -60.01% | 68.76% | -55173.99% |
| EBITDA | -38,342 | -5,467 | 97,377 | -42,358 |
| EBITDA Margin | - | -26.15% | 71.91% | - |
| D&A For EBITDA | 3,068 | 2,868 | 1,771 | 1,290 |
| EBIT | -41,410 | -8,335 | 95,607 | -43,648 |
| EBIT Margin | - | -39.87% | 70.60% | - |
| Advertising Expenses | - | 4.37 | 3.95 | 10.28 |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.